cf revenue handili beat consensu guidanc rais
trikafta penetr major elig
cf patient impli revenue growth slower nonetheless expect
expans new territori age drive revenue compound-annual-growth-rate
increas
vertex report cystic fibrosi cf franchis revenu q/q
y/i ahead consensu estim includ
trikafta manag estim trikafta penetr major
elig cf patient disclos benefit earli refil
advanc buy relat non-gaap ep ahead
consensu
vertex increas cf revenu guidanc reflect
trend quarter ahead manag anticip revenu growth moder
due plateau trikafta uptak earli prescript refil
advanc buy govern payor ex-u seen hospit limit
non-emerg patient visit may reduc new patient start
adjust est consist guidanc dcf-base price target
increas
begun ph ii proof-of-concept studi first candid antitrypsin
approx patient defici enrol paus late
march due tonight disclos re-initi site-by-sit
basi manag believ earli say whether impact time
data previous anticip late
vertex leader develop candid treat cystic fibrosi vertex
strong commerci busi capabl withstand therefor
guidanc product revenu appear achiev base
promis trikafta project revenu compound-annual-growth-rate
non-gaap ep compound-annual-growth-rate among highest larg cap biotech trikafta expect
patent protect vertex franchis long commerci
life anticip potenti non-cf pipelin becom clearer
next month poc data read-out fg expect vertex stock
outperform cystic fibrosi portfolio drive industry-lead revenu ep growth
vertex non-cf pipelin gener proof-of-concept
pleas see page report import disclosur
vertex develop portfolio therapi cystic fibrosi breakthrough
treatment cf patient harbor least one allel cftr potenti
kalydeco first approv patient gate partial loss function
mutat orkambi cftr corrector lumacaftor kalydeco approv
juli symdeko tezacaftor kalydeco februari tripl combin
trikefta contain gener corrector well tezacaftor ivacaftor
produc impress ph data appear like improv qualiti life extend
life span patient trikefta fda approv octob
file review model assum cystic fibrosi patient
one vertex therapi drive nearli franchis sale dcf-base price
target
updat phase i/ii data gene-
therapi like eha
like ema approv trikafta
phase ii data possibl
cystic fibrosi patient
one vertex therapi
drive franchis sale
franchis maintain exclus
rest pipelin contribut
cystic
fibrosi patient one vertex
therapi drive
franchis sale
franchis maintain exclus
anoth vertex pipelin program
fewer cystic
fibrosi patient one vertex
therapi drive less
franchis sale
vertex face meaning competit
vertex leader treatment cystic fibrosi symdeko orkambi kalydeco
standard therapi cystic fibrosi patient homozyg mutat
rate residu function mutat vertex gener strike phase data
tripl combin regimen incorpor second gener corrector
min patient regimen approv two month fda review octob
appear repres true breakthrough treatment improv qualiti
life extend life span cystic fibrosi world-wide moreov patent
protect late vertex franchis long commerci life
early-stag pipelin includ candid antitrypsin defici pain sickl
cell diseas beta-thalassemia focal segment glomerulosclerosi initi proof-of-
concept data program may come late earli
vertex report cystic fibrosi cf franchis revenu q/q y/
trikfata revenu first full quarter market vs
first two month market includ inventori build addit
trikafta revenu also includ kalydeco sale q/q y/i
orkambi q/q y/i symdeko revenu q/q
y/i note revenu benefit order pull forward
due covid combin non-gaap sg vs
yield non-gaap ep ahead consensu
importantli compani remain confid suppli chain cf medicin
expect commerci oper materi impact
manag note vertex suffici drug suppli hand deliv product
patient sever month meanwhil manufactur facil remain activ
continu produc new drug suppli patient vertex medicin
deliv home requir physician visit receiv vertex
work distributor ensur patient deliveri interrupt
octob vertex announc fda approv trikafta elexacaftor/
tezacaftor/ivacaftor treatment cystic fibrosi cf patient age year
older least one mutat drug becam avail market
week later approv came approxim five month trikafta march
pdufa two month accept nda august approv
mark first time het min patient approxim peopl age
medicin treat underli caus diseas vertex estim
anoth approxim cf patient elig one compani fda-
approv cf medicin also elig trikafta
tonight call manag note estim major
approxim cf patient elig trikafta alreadi initi
treatment suggest pace growth revenu slow
next sever quarter particularli sinc caus order pull
nonetheless expect vertex cf revenu continu grow
higher rate complianc persist trikafta anticip approv
trikafta europ expans trikafta indic includ children young
trikafta file ema approv anticip later year upon
approv trikafta becom avail cf patient countri vertex
establish portfolio reimburs agreement ireland denmark switzerland
australia netherland well germani vertex work achiev addit
reimburs agreement country-by-countri basi
phase trial trikafta patient age fulli enrol vertex work
ensur patient receiv drug home interrupt dose
snda plan submiss
given high demand health care resourc respond pandem vertex
proactiv decid chang on-going plan clinic trial
vertex first candid antitrypsin complet sad
mad studi healthi volunt phase ii proof-of-concept dose-find studi
approxim patient defici two mutat
initi enrol paus late march due pandem
re-initi site-by-sit basi manag believ earli say whether
paus impact time data read-out previous anticip late
base preclin data vertex expect correct fold reduc
aggreg form liver allow protein travel lung
phase ii vertex look increas function show proof-of-
concept vertex also advanc second small molecul corrector phase
develop risk mitig purpos vertex may take multipl candid phase
ii done cf
novemb vertex partner crisper announc posit interim data
first two patient sever hemoglobinopathi one transfusion-depend
beta thalassemia one sever sickl cell diseas treat gene-edit therapi
on-going phase i/ii trial enrol on-going approxim six site
beta thalassemia patient approxim enrol scd howev vertex
paus initi condit dose new patient light
updat data still expect present data includ long-term
follow first two patient initi data addit patient enrol
dose earlier year
vertex recent initi phase ii open-label proof-of-concept studi
mediat focal segment glomerulosclerosi fsg primari endpoint percent
chang baselin urin protein creatinin ratio upcr week manag
anticip enrol trial like slow though work mitig
impact fsg character proteinuria patient typic progress develop
impair kidney function vertex estim approxim patient
fsg homozyg mutat vertex sever
inhibitor candid treatment fsg preclin develop
septemb vertex announc acquisit compani
develop stem cell-deriv human islet potenti cur treatment type
diabet vertex continu plan advanc cell therapi program clinic
develop late earli
final initi phase ii dose-rang studi once-daili potenti
monotherapi support develop part once-daili tripl clinicaltri gov
list primari complet date june compani plan initi
phase develop once-daili tripl regimen also evalu
combin third-gener corrector tezecaftor phase ii studi
accord clinicaltri gov trial complet decemb impli initi
phase program later year
vertex leader discoveri develop candid treat cystic
fibrosi vertex develop portfolio therapi cystic fibrosi
standard care treatment cf patient harbor least one
allel vertex first cystic fibrosi commerci product kalydeco ivacaftor
cftr potenti compound kalydeco approv fda
januari patient gate mutat mutat
addit residu function mutat ad label seri
cftr corrector lumacaftor tezacaftor broaden use beyond partial loss-of-
function mutat includ cystic fibrosi patient homozyg
mutat orkambi lumacaftor ivacaftor succeed two pivot trial june
approv juli symdeko tezacaftor ivacaftor produc
posit data two phase trial march fda approv februari
european approv came novemb brand name
symkevi improv potenc orkambi symdeko
homozygot effect patient one copi allel
vertex develop second gener corrector act synergist
lumacaftor tezacaftor complet correct fold defect
cftr trikafta combin tezacaftor ivacaftor second-gener once-daili
corrector elexacaftor produc impress phase data approv fda
octob brief two month review trikafta appear repres true
breakthrough treatment improv qualiti life extend life span
patient cystic fibrosi world-wide least one copi
mutat moreov second-gener corrector expect
patent protect vertex franchis long commerci
life model cystic fibrosi patient one vertex therapi
drive almost franchis sale impli industry-lead growth
dcf-base price target base industry-lead growth
approv symkevi eu patient age
possibl releas data phase ii tezacaftor
possibl ema approv trikafta
possibl in-licens acquisit addit product candid
addit data sickl cell diseas beta thalassemia
file fda approv trikafta patient age
phase ii data first corrector
advanc cell therapi type diabet clinic develop
cowen compani
cowen compani
statesnumb patient diagnos patient penetr patient kalydeco per patient patient gate gate penetr patient kalydeco per patient patient gate mutat homozyg homozyg regimen penetr patient vertex per patient patient heterozyg heterozyg regimen penetr patient vertex per patient hetero patient vertex kalydeco orkambi/symdeko/trikafta cystic fibrosi revenu patient diagnos patient penetr patient per patient gate gate penetr patient per patient patient gate homozyg regimen penetr patient vertex per patient heterozyg heterozyg regimen penetr patient vertex per patient hetero row patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu gate mutat gate mutat patient orkambi/symdeko/tripl cystic fibrosi patient vertex cystic fibrosi cowen
cowen compani
fy dec except per symdeko tripl growth expensescost good product develop ex gener administr ex base cost loss incom rate incom loss attribut non-controlling interestnet lncome exclud soe exclud soe expens net share share cowen
cowen compani
fy dec except per cagrrevenu kalydeco symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex cost incometot loss incom rate lncome exclud soe exclud soe expens net share cowen
cowen compani
financi year incivek cystic fibrosi payment tax asset unus tax free year growth ratetermin valu termin valu net per valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
vertex deriv great major revenu market cf product forecast
sale thisfranchis difficult outlook could alter new safety/
efficaci find emerg competit alter medic treatment paradigm
chang pricing/reimburs environ vertex stock price could also
affect chang outlook key pipelin program includ
evalu market potenti drug yet approv
